Vyne Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

YARROW BIOSCIENCE

14/08/2024 14:11

* Vyne Therapeutics Inc  VYNE.OQ  reported a quarterly
adjusted
loss of 22 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-3.09.  The mean expectation of two analysts
for the quarter was for a loss of 19 cents per share. 
    * Revenue rose 46.7% to $198.00 thousand from a year ago;
analysts
expected $110.00 thousand. 
    * Vyne Therapeutics Inc's reported EPS for the quarter was a
loss
of 22 cents​.
    * The company reported a quarterly loss of $9.41 million.
    * Vyne Therapeutics Inc shares had fallen by 13.2% this
quarter and lost 26.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Vyne Therapeutics
Inc is $5.75 
This summary was machine generated from LSEG data August 14 at
01:10 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.19          -0.22          Missed
 Mar. 31 2024      -0.24          -0.15          Beat
 Dec. 31 2023      -0.50          -0.20          Beat
 Sep. 30 2023      -0.76          -2.01          Missed